Close Menu

Myriad

Mother Jones reports that some data used for interpreting what BRCA1 or BRCA2 mutations mean are kept private.

The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.

Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.

Researchers from the molecular diagnostics firm said their screen could identify a range of variant types to boost the identification of at-risk couples.

The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.

The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.

Genetic tests may help psychiatrists choose which drugs to start their patients on, the Wall Street Journal reports.

Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.

A Phase III randomized trial uncovered enhanced carboplatin response in advanced triple-negative breast cancer patients with germline mutations affecting BRCA1/2.

The lawsuits were filed after the HHS OIG subpoenaed the firm as part of an investigation into how it billed Medicare and Medicaid for the myRisk test.

Pages

Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.

Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.

Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.

In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.